Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.44 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.33 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 5/20 | 0.32 |
| ▸ | MMP3 | P08254 | 5/20 | 0.32 |
| ▸ | MMP1 | P03956 | 3/20 | 0.32 |
| ▸ | MMP7 | P09237 | 1/20 | 0.32 |
| ▸ | Q9HBH1 | 1/20 | 0.32 | |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005618 | 1.00 | DPP8 (0.44) | DPP8DPP4DPP9DPP7FAP | |
| SCHEMBL4009951 | 1.00 | DPP8 (0.44) | DPP8DPP4DPP9DPP7FAP | |
| SCHEMBL4014990 | 1.00 | DPP8 (0.44) | DPP8DPP4DPP9DPP7FAP | |
| SCHEMBL4009002 | 0.92 | DPP7 (0.52) | DPP8DPP4DPP9DPP7FAP | |
| SCHEMBL4009810 | 0.92 | DPP7 (0.52) | DPP8DPP4DPP9DPP7FAP | |
| SCHEMBL4009825 | 0.92 | DPP7 (0.52) | DPP8DPP4DPP9DPP7FAP | |
| SCHEMBL4012008 | 0.92 | DPP7 (0.52) | DPP8DPP4DPP9DPP7FAP | |
| SCHEMBL4010250 | 0.90 | ENPEP (0.37) | DPP8DPP4DPP9DPP7ENPEP | |
| SCHEMBL4010376 | 0.90 | ENPEP (0.37) | DPP8DPP4DPP9DPP7ENPEP | |
| SCHEMBL4008845 | 0.90 | ENPEP (0.37) | DPP8DPP4DPP9DPP7ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | claimed |
| EP-1670750-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | claimed |
| WO-2005030703-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | claimed |
| US-7491835-B2 | Prodrugs of amino acids with affinity for the α2δ-protein | PFIZER INC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1670750-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN | Warner-Lambert Company LLC (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005030703-A1 | PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | VIATRIS SPECIALTY LLC. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070483-A1 | Prodrugs of amino acids with affinity for the alpha2delta-protein | SCN2A, OPRD1, SCN1A | DPP8 2187/4885DPP4 1906/4885DPP9 2414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.